427 related articles for article (PubMed ID: 35188528)
1. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.
Greenhawt M; Abrams EM; Shaker M; Chu DK; Khan D; Akin C; Alqurashi W; Arkwright P; Baldwin JL; Ben-Shoshan M; Bernstein J; Bingemann T; Blumchen K; Byrne A; Bognanni A; Campbell D; Campbell R; Chagla Z; Chan ES; Chan J; Comberiati P; Dribin TE; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Grayson MH; Horner CC; Hourihane J; Katelaris CH; Kim H; Kelso JM; Lang D; Ledford D; Levin M; Lieberman J; Loh R; Mack D; Mazer B; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Oppenheimer J; Perrett KP; Ramsey A; Rank M; Robertson K; Sheikh J; Spergel JM; Stukus D; Tang MLK; Tracy JM; Turner PJ; Whalen-Browne A; Wallace D; Wang J; Waserman S; Witry JK; Worm M; Vander Leek TK; Golden DBK
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3546-3567. PubMed ID: 34153517
[TBL] [Abstract][Full Text] [Related]
3. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
Greenhawt M; Dribin TE; Abrams EM; Shaker M; Chu DK; Golden DBK; Akin C; Anagnostou A; ALMuhizi F; Alqurashi W; Arkwright P; Baldwin JL; Banerji A; Bégin P; Ben-Shoshan M; Bernstein J; Bingemann TA; Bindslev-Jensen C; Blumenthal K; Byrne A; Cahill J; Cameron S; Campbell D; Campbell R; Cavender M; Chan ES; Chinthrajah S; Comberiati P; Eastman JJ; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Garvey LH; Grayson MH; Isabwe GAC; Hartog N; Hendron D; Horner CC; Hourihane JO; Iglesia E; Kan M; Kaplan B; Katelaris CH; Kim H; Kelso JM; Khan DA; Lang D; Ledford D; Levin M; Lieberman JA; Loh R; Mack DP; Mazer B; Mody K; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Nathan R; Oppenheimer J; Otani IM; Park M; Pawankar R; Perrett KP; Peter J; Phillips EJ; Picard M; Pitlick M; Ramsey A; Rasmussen TH; Rathkopf MM; Reddy H; Robertson K; Rodriguez Del Rio P; Sample S; Sheshadri A; Sheik J; Sindher SB; Spergel JM; Stone CA; Stukus D; Tang MLK; Tracy JM; Turner PJ; Vander Leek TK; Wallace DV; Wang J; Wasserman S; Weldon D; Wolfson AR; Worm M; Yacoub MR
J Allergy Clin Immunol; 2023 Aug; 152(2):309-325. PubMed ID: 37295474
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: A systematic review and meta-analysis.
Greenhawt M; Shaker M; Golden DBK; Abrams EM; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Chu DK; Dwamena BA
Allergy; 2023 Jan; 78(1):71-83. PubMed ID: 36321821
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.
Patel GB; Chhiba KD; Chen MM; Guo A; Watts MM; Cullen J; Bochner BS; Grammer LC; Greenberger PA; Saltoun CA; Stevens WW; Kuang FL; Peters AT
Allergy Asthma Proc; 2021 Nov; 42(6):515-521. PubMed ID: 34871159
[No Abstract] [Full Text] [Related]
7. Anaphylaxis is a rare reaction in COVID-19 vaccination.
Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P
J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336
[TBL] [Abstract][Full Text] [Related]
8. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
Wolfson AR; Robinson LB; Li L; McMahon AE; Cogan AS; Fu X; Wickner P; Samarakoon U; Saff RR; Blumenthal KG; Banerji A
J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3308-3320.e3. PubMed ID: 34166844
[TBL] [Abstract][Full Text] [Related]
9. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination.
Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG
JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis.
Rahman MO; Kamigaki T; Thandar MM; Haruyama R; Yan F; Shibamura-Fujiogi M; Khin Maung Soe J; Islam MR; Yoneoka D; Miyahara R; Ota E; Suzuki M
BMJ Open; 2023 Dec; 13(12):e076892. PubMed ID: 38128943
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
14. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
Banerji A; Wickner PG; Saff R; Stone CA; Robinson LB; Long AA; Wolfson AR; Williams P; Khan DA; Phillips E; Blumenthal KG
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1423-1437. PubMed ID: 33388478
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
16. Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.
Kaplan B; Farzan S; Coscia G; Rosenthal DW; McInerney A; Jongco AM; Ponda P; Bonagura VR
Ann Allergy Asthma Immunol; 2022 Feb; 128(2):161-168.e1. PubMed ID: 34699968
[TBL] [Abstract][Full Text] [Related]
17. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
18. A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination.
Khalid MB; Zektser E; Chu E; Li M; Utoh J; Ryan P; Loving HS; Harb R; Kattappuram R; Chatman L; Hartono S; Claudio-Etienne E; Sun G; Feener EP; Li Z; Lai SK; Le Q; Schwartz LB; Lyons JJ; Komarow H; Zhou ZH; Raza H; Pao M; Laky K; Holland SM; Brittain E; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2024 Jun; 153(6):1634-1646. PubMed ID: 38460680
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan.
Higashino T; Yamazaki Y; Senda S; Satou Y; Yonekura Y; Imai K; Arakawa J; Kawano S; Horinosono H; Miura Y
JAMA Dermatol; 2022 Aug; 158(8):923-927. PubMed ID: 35649530
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
